Effects of landiolol, an ultra-short-acting β1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs

Circulation Journal

Volumn 74, Issue 5, 2010, Pages 856-863

  Miwa, Yosuke ^a   Ikeda, Takanori ^a   Mera, Hisaaki ^a   Miyakoshi, Mutsumi ^a   Hoshida, Kyoko ^a   Yanagisawa, Ryoji ^a   Ishiguro, Haruhisa ^a   Tsukada, Takehiro ^a   Abe, Atsuko ^a   Yusu, Satoru ^a   Yoshino, Hideaki ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

blocker; Antiarrhythmic drug; Electrical storm; Landiolol; Ventricular tachyarrhythmia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; LANDIOLOL; NIFEKALANT;

ADULT; AGE; AGED; APACHE; ARTERIAL GAS; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG RESPONSE; DRUG TREATMENT FAILURE; ELECTRICAL STORM; ELECTROCARDIOGRAM; FEMALE; HEART PACING; HEART RATE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LOW DRUG DOSE; MALE; PROGNOSIS; QT PROLONGATION; SIDE EFFECT; SURVIVAL RATE; SURVIVOR; TORSADE DES POINTES; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; DRUG RESISTANCE; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; TACHYCARDIA, VENTRICULAR; UREA;

EID: 77951874372     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0772     Document Type: Article

References (28)

1. ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2006; 48: e247-e346.
2. ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction-Executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2004; 110: 588-636.
3. AHA 2005 guidelines for cardiopulmonary resuscitation and emergency cardiovascular care: ECC committee, subcommittees and task forces of the American Heart Association. Circulation 2005; 112(Suppl IV): IV-1-IV-203.
4. JCS 2008 guidelines for the treatment of patients with ST-elevation acute myocardial infarction: A report of the Japanese Circulation Society committee for diagnosis and treatment of cardiovascular diseases. Circ J 2008; 72(Suppl IV): IV-1347-IV-1442.
5. Exner DV, Pinski SL, Wyse DG, Renfroe EG, Follmann D, Gold M, et al. Electrical storm presages nonsudden death: The antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation 2001; 103: 2066-2071.
6. Bänsch D, Bocker D, Brunn J, Weber M, Breithardt G, Beck M. Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators. J Am Coll Cardiol 2000; 36: 566-573.
7. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002; 346: 884-890.
8. Washizuka T, Chinushi M, Watanabe H, Hosaka Y, Komura S, Sugiura H, et al. Nifekalant hydrochloride suppresses severe electrical storm in patients with malignant ventricular tachyarrhythmias. Circ J 2005; 69: 1508-1513.
9. Yusu S, Ikeda T, Mera H, Miyakoshi M, Miwa Y, Abe A, et al. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. Circ J 2009; 73: 2021-2028.
10. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: Sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000; 102: 742-747.
11. Tsagalou EP, Kanakakis J, Rokas S, Anastasiou-Nana MI. Suppression by propranolol and amiodarone of an electrical storm refractory to metoprolol and amiodarone. Int J Cardiol 2005; 99: 341-342.
12. Lombardi F, Verrier RL, Lown B. Relationship between sympathetic neural activity, coronary dynamics and vulnerability to ventricular fibrillation induced by myocardial ischemia and reperfusion. Am Heart J 1983; 105: 958-965.
13. Zipes DP. Influence of myocardial ischemia and infarction on autonomic innervation of heart. Circulation 1990; 82: 1095-1105.
14. Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, et al. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull 1992; 40: 1462-1469.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829.
16. Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther 2000; 68: 143-150.
17. Motomura S, Hagihara A, Narumi Y, Hashimoto K. Time course of a new ultrashort-acting beta-adrenoceptor-blocking drug, ONO1101: Comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations. J Cardiovasc Pharmacol 1998; 31: 431-440.
18. Kowey PR. An overview of antiarrhythmic drug management of electrical storm. Can J Cardiol 1996; 12: 3B-8B.
19. Burjorjee JE, Milne B. Propofol for electrical storm; a case report of cardioversion and suppression of ventricular tachycardia by propofol. Can J Anaesth 2002; 49: 973-977.
20. Bänsch D, Oyang F, Antz M, Arentz T, Weber R, Val-Mejias JE, et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation 2003; 108: 3011-3016.
21. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331-336.
22. Maggioni AP, Zuanetti G, Franzosi MG, Rovelli F, Santoro E, Staszewsky L, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era: GISSI-2 results. Circulation 1993; 87: 312-322.
23. Rydén L, Ariniego R, Arnman K, Herlitz J, Hjalmarson A, Holmberg S, et al. A double-blind trial of metoprolol in acute myocardial infarction Effects on ventricular tachyarrhythmias. N Engl J Med 1983; 308: 614-618.
24. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction Arrhythmias. Am J Cardiol 1985; 56: 35G-38G.
25. Pratt C, Lichstein E. Ventricular antiarrhythmic effects of betaadrenergic blocking drugs: A review of mechanism and clinical studies. J Clin Pharmacol 1982; 22: 335-347.
26. Lichstein E, Morganroth J, Harrist R, Hubble E. Effect of propranolol on ventricular arrhythmia: The beta-blocker heart attack trial experience. Circulation 1983; 67: I-5-I-10.
27. Morganroth J. Antiarrhythmic effects of beta-adrenergic blocking agents in benign or potentially lethal ventricular arrhythmias. Am J Cardiol 1987; 60: 10D-14D.
28. Singh BN. β-blockers and calcium channel blockers as antiarrhythmic drugs. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: From cell to bedside, 4th edn. Philadelphia: Saunders, 2004; 918-931.